In the last trading session, 2.0 million shares of the Intellia Therapeutics Inc (NASDAQ:NTLA) were traded, and its beta was 1.97. Most recently the company’s share price was $9.58, and it changed around -$0.21 or -2.15% from the last close, which brings the market valuation of the company to $975.71M. NTLA currently trades at a discount to its 52-week high of $34.87, offering almost -263.99% off that amount. The share price’s 52-week low was $9.25, which indicates that the current value has risen by an impressive 3.44% since then. We note from Intellia Therapeutics Inc’s average daily trading volume that its 10-day average is 2.55 million shares, with the 3-month average coming to 2.78 million.
Intellia Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.57. If we narrow it down even further, the data shows that 0 out of 28 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 7 recommended NTLA as a Hold, whereas 17 deemed it a Buy, and 0 rated it as Underweight.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Instantly NTLA has showed a red trend with a performance of -2.15% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 10.73 on recent trading dayincreased the stock’s daily price by 10.72%. The company’s shares are currently down -17.84% year-to-date, but still up 0.42% over the last five days. On the other hand, Intellia Therapeutics Inc (NASDAQ:NTLA) is -20.30% down in the 30-day period. We can see from the shorts that 24.06 million shares have been sold at a short interest cover period of 8.36 day(s).
The consensus price target as assigned by Wall Street analysts is $39, which translates to bulls needing to increase their stock price by 75.44% from its current value. Analyst projections state that NTLA is forecast to be at a low of $18 and a high of $60.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -22.30%. Intellia Therapeutics Inc earnings are expected to increase by 1.99% in 2025, but the outlook is positive 2.76% per year for the next five years.
NTLA Dividends
Intellia Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.27% of Intellia Therapeutics Inc shares, and 92.37% of them are in the hands of institutional investors. The stock currently has a share float of 97.50%. Intellia Therapeutics Inc stock is held by 418.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 12.1419% of the shares, which is about 11.6 million shares worth $259.51 million.
BLACKROCK INC., with 10.0496% or 9.6 million shares worth $214.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 8.62 shares worth $82.6 million, making up 8.47% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 3.17 shares worth around $30.42 million, which represents about 3.12% of the total shares outstanding.
